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For those surviving encephalitis, the influence on daily life of patients and their relatives may be 
substantial. In contrast, the prognosis after aseptic meningitis (ASM) is considered good. In this 
prospective study in patients with encephalitis (n = 20) and ASM (n = 46), we show that both groups 
experienced reduced Health Related Quality of Life (HRQoL) at two months after discharge, and that 
workability was reduced in 37% of the patients with ASM. However, 12 months after discharge no 
neuropsychological deficits were detected in the ASM group, whereas patients with encephalitis had 
lower scores on tests of fine motor and psychomotor skills as well as on learning and memory. We 
also found that for patients with encephalitis, neopterin, as a marker of Th1 cell induced macrophage 
activation, and a putatively neurotoxic ratio of the kynurenine pathway (KP) measured during the acute 
phase was associated with lower HRQoL. Our data show that not only encephalitis, but also ASM has 
substantial short-term influence on HRQoL and workability. For patients with encephalitis we suggest a 
link between immune activation and activation of the KP during the acute phase with impaired HRQoL.
Infectious encephalitis is an inflammatory condition of the brain parenchyma. The most common identified cause 
is the herpes simplex type I (HSV-1), which left untreated has a mortality of 70%1. In contrast, aseptic meningitis 
(ASM) is considered a more benign condition with low mortality even without specific treatment2.
Studies regarding quality of life and neurocognitive sequela after encephalitis and ASM are scarce, most stud-
ies are agent specific (e.g. only HSV-1) and comparison between studies is hampered by divergent inclusion 
criteria, diversity in tests performed and follow-up time3–5. Many patients with encephalitis remain undiagnosed 
regarding causing agent, and few studies have investigated outcome for various or unknown etiologies6,7. Data 
concerning outcome and disability after ASM vary from no complains, to reduced Health Related Quality of Life 
(HRQoL), fatigue, and reduced cognitive function8–12.
Except from being vital for pathogen clearance in the CNS, several studies have demonstrated that immune 
activation and activation of the kynurenine pathway (KP) is associated with outcome of CNS infections13–17. 
Whereas a balanced immune response is beneficial for the host, an overwhelming activation of inflammatory 
pathways could be harmful. Activation of the KP pathway can also mediate harmful as well as protective effect 
on CNS during infections, depending on the balance between the metabolites of KP. Kynurenic acid (KYNA) has 
neuroprotective effects whereas quinolinic acid (QA) mediates excitotoxicity, and both have been associated with 
depression and impaired cognitive function18–20. Recently we reported a state of generalized immune activation 
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and increased levels of KP metabolites in the cerebrospinal fluid (CSF) from patients with encephalitis and ASM 
compared to patients without CNS infection21. Moreover, for patients with encephalitis we found that neop-
terin, as a marker of interferon (IFN)-γ activity, correlated with the rate-limiting step of the KP (i.e. indoleamine 
2,3-dioxygenase (IDO)) and with a putative neurotoxic ratio of the KP.
In the present study, we aimed to evaluate workability and HRQoL in patients with acute encephalitis and 
ASM of various and unknown etiology two months after discharge. Secondly, we accessed long-term neuropsy-
chological outcome at 12 months. We also aimed to investigate whether short-term outcome was related to clin-
ical findings and previously reported, dysregulated neopterin and KP metabolites during the acute phase of the 
infection.
Methods
Study design and patients. This prospective observational study was performed at Oslo University 
Hospital, Ullevål between January 2014 and June 2018. During the first two years (2014–2015) all patients pre-
senting with acute symptoms of CNS infection at the Department of Medicine and Neurology who underwent a 
lumbar puncture (LP) were included (n = 244). Of these, 32 of the 45 patients who fulfilled the case definition of 
ASM and 12 of the 19 patients who fulfilled the inclusion criteria of encephalitis were included in the follow-up 
study. During the last inclusion period (March 2016-June 2018) only patients from the Department of Infectious 
Diseases were eligible for inclusion, of 19 cases with ASM, 14 patients were included, whereas all patients diag-
nosed with encephalitis in this latter inclusion period fulfilled inclusion criteria for the follow-up study (Fig. 1). 
The case definition of encephalitis is, as previously published, based on the same criteria and symptoms as stated 
in the International Encephalitis Consortium case definition (Table 1)22,23. The case definition of ASM is based on 
a consortium definition published by Tapiainen et al. (Table 1)24. Nine patients with ASM had prior to the lumbar 
puncture been treated with antibiotics, which could results in false negative CSF culturing. For three of these 
patients, no causing agent was identified, and a negative polymerase chain reaction (PCR) for common causes of 
bacterial meningitis was required to fulfill the case definition. None of the patients had a positive blood culture. 
For all patients in this study, in-house real time polymerase chain reaction (PCR) for detection of herpes simplex 
virus 1 (HSV1) and 2 (HSV2), varicella zoster virus (VZV) and enterovirus were carried out. Analyses for detec-
tion of other microbiological agents in CSF and serum were analyzed if clinically relevant23.
Figure 1. Flowchart showing inclusion of patients. SF-36: Survey Short Form, HAD: Hospital Anxiety and 
Depression Scale, GOSE: Glasgow Outcome Scale Extended.
Condition Case definition
Encephalitis
Encephalopathy (altered mental function or change in personality) for >24 hours 
with no other cause identified and at least two of the following:
1. ≥ 5 × 106/L leucocytes (WBC) in cerebrospinal fluid (CSF)
2. new onset of seizures,
3. new onset of focal neurology,
4. documented fever >38°C before or within 24 hours after hospitalisation,
5. EEG findings suggestive of encephalitis and/or
6. MRI/CT findings suggestive of encephalitis
Aseptic meningitis (ASM)
1. Clinical signs of meningitis (headache, neck stiffness, photophobia and/or fever),
2. ≥ 5 × 106/L leucocytes in CSF and
3. culture and microscopy negative CSFa
Table 1. Case definitions. aFor patients treated with antibiotics prior to LP, a negative bacterial PCR for 
common causes of bacterial meningitis was required.
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A follow up appointment was scheduled two months after discharge (Fig. 1). Patients with encephalitis 
and patients diagnosed with ASM after September 2016 were invited to neuropsychological testing 12 months 
after infection. Patients with premorbid chronic psychiatric disease, addictive disorders or patients with poor 
Norwegian language skills were excluded. Two patients in the encephalitis group had recently been tested and 
were excluded from the neuropsychological testing due to test-retest bias (Fig. 1).
patient characteristics and clinical data. Clinical and demographic data were obtained during hospital 
admittance as described in our previous work (Table 2)23. Etiological agents were classified using the criteria given 
in the review of Granerod et al.25. From seven patients with encephalitis and 10 ASM patients, measurements of 
tryptophan [TRP], kynurenine [KYN], anthranilic acid [AA], kynurenic acid [KYNA], 3-hydroxykynurenine 
[3-HK], 3-hydroxyanthranilic acid [3-HAA], quinolinic acid [QA], picolinic acid [PIC], and neopterin from CSF 
and serum sampled at admission were known. These measurements were analyzed by liquid chromatography- 
tandem mass spectrometry (LC-MS/MS) as previously described21,26. From previous published data, the calcu-
lated ratio (KYN/TRP) of the rate-limiting enzyme of the KP in the CNS, i.e. indolamine 2,3-dioxygenase (IDO) 
and the putatively neuroprotective (i.e. KYNA) to neurotoxic KP metabolites (i.e. 3-HK + QA) were known21.
Short-term follow up. The clinical follow-up included a structured interview on persisting complains and 
workability (Table 3), the Glasgow Outcome Scale extended (GOSE)27, the Hospital Anxiety and Depression Scale 
(HAD)28 and the Survey Short Form (SF-36)29. The eight scales of the SF-36 were aggregated in two summary 
component scores, the Physical (PCS) and Mental (MCS) Component Summary scores30.
neuropsychological testing and long-term follow up. A wide range of neuropsychological tests was 
used to measure cognitive function 12 months after discharge from hospital. The chosen neuropsychological test 
battery was similar to that used in a follow-up study on patients with neuroborreliosis31, and was designed to 
evaluate a broad range of cognitive abilities (Table 4)32–39.
ethical considerations. All patients gave a written informed consent. The study was approved by The 
Regional Committees for Medical and Health Research Ethics (REC South East, reference number 2011/2578) 
and the hospital ethical council, and was conducted according to relevant guidelines and regulations.
Encephalitis (n = 20) Aseptic meningitis (n = 46) p-value
Gender, male, no (%) 10/20 (50) 16/46 (35) ns
Ageb 53 (29) 34 (11) <0.001
Stay in intensive care unit (%) 8/20 (40) 2/46 (4) <0.001
Etiology, confirmed/probablec (%) 5/20 (25) 34/46 (74) <0.001
Days in hospitalb 14 (13) 3 (2) <0.001
Days since ictusb 1 (3) 1 (1) ns
Headache (%) 12/20 (60) 46/46 (100) <0.001
Neck stiffness, subjective (%) 3/19 (16) 31/46 (67) <0.001
Photophobia (%) 7/20 (35) 32/46 (70) 0.009
Clinical findings
Objective neck stiffness (MD) (%) 5/19 (26) 22/46 (48) ns
Seizures (%) 2/17 (12) 0 0.027
Focal findings (%) 9/20 (45) 3/ 42 (7) <0.001
Objective fever (%) 14/20 (70) 29/46 (63) ns
Temperature, admissiona 37.3 (1.0) 37.3 (0.9) ns
MR typical for encephalitis (n =  31) 4/18 (22) 0/13 (0) ns
EEG suggestive of encephalitis (n = 18) 10/16(63) 0/2 (0) ns
Laboratory findings
WBC in serum (n = 66)a 9.7 (3.1) 8.9 (2,3) ns
CRP (n = 65)b 5.7 (21) 4.7 (9) ns
CSF- WBCb 65 (256) 243 (409) ns
CSF- proteinsb 0.909 (0.907) 0.675 (0.531) 0.017
CSF- glucosea 3.5 (0.6) 3.3 (0.6) ns
CSF- glucose ratio (n = 50)a 0.56 (0.13) 0.56 (0.09) ns
Treatment during hospital stay
Aciclovir iv, no (%) 18/20 (90) 34/46 (74) ns
“CNS- antibiotics”, no (%) 14/20 (70) 28/46 (61) ns
Table 2. Demographic, laboratory and clinical characteristics of patients. Data are presented as number (%), 
amean (SD) or bmedian (IQR). cEtiology in encephalitis were; VZV (n = 2), HSV1 (n = 1), B. burgdorferi (n = 2). 
Aseptic meningitis; EV (n = 20), HSV2 (n = 10), VZV (n = 2), Toscana virus (n = 1), B. burgdorferi (n = 1).
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Statistics. Categorical variables are expressed as counts (percentages) and comparisons between groups were 
done using Pearson Chi-square test for categorical data. Continuous data are presented as mean (SD) if normally 
distributed, otherwise as median (interquartile range, IQR). Comparisons of continuous data were analyzed using 
T-test for normally distributed data, otherwise Mann-Whitney-U was used. Results of questionnaires and neu-
ropsychological tests are presented as mean raw scores with standard deviations (SD). One-sided T-test was used 
to compare SF-36 data to normative data matched on age and sex40,41. For PCS and MCS a population mean of 
50 was used. To compare results of neurocognitive tests with expected mean, z-scores were calculated. A z-score 
below −1 SD was considered a deficit. Associations between HRQoL and measurements of immune activation 
and KP metabolites at admittance were performed with Spearman’s rank correlation. Due to the limited sample 
size, we restricted our correlation analysis with SF-36 measures to previously identified dysregulated KP pathway 
measures (i.e. neopterin, IDO and KYNA/(3-HK + QA)) to minimize the influence of multiple testing30. To limit 
type II statistical errors, no correction for multiple comparisons was made in this explorative study42. All data 
analyses were performed in SPSS version 24 (IBM Corp. Armonk, NY, USA) and graphs generated by Graphad 
Prism 8 (GraphPad, San Diego, USA).
Encephalitis (n = 20) Aseptic meningitis (n = 46) p-value
Time to follow-up, daysb 79 (60) 62 (44) 0.048
No reported complaints (%) 1/20 (5) 17/46 (37) 0.007
Sick leave, total no (%) 12/12 (100) 16/43 (37) <0.001
  100% unable to work (%) 7/12 (58) 5/43 (12) 0.002
GOSE
GOSE <4 1 (5) 0
0.007GOSE = 5–6 14 (74) 18 (39)
GOSE = 7–8 4 (21) 28 (61)
SF-36 subscoresa
Physical functioning (PF) 78.5 (21) 89.3 (18) ns
Role physical (RP) 16.2 (32) 45.2 (48) 0.01
Role emotional (RE) 58.8 (42) 77.4 (38) ns
Bodily pain (BP) 68.9 (28) 65.7 (25) ns
General health (GH) 61.8 (21) 66.6 (27) ns
Vitality (VT) 45 (15) 51.1 (23) ns
Social functioning (SF) 61.8 (26) 71.1 (31) ns
Mental health (MH) 73.2 (14) 79.2 (15) ns
Physical component summary (PCS) 43.6 (8) 46.7 (10) ns
Mental component summary (MCS) 45 (8) 49 (11) ns
HAD
HAD sum A, median
Sum 0–7, no of patients (%) 15 (88) 34 (79) ns
Sum 8–10, no of patients (%) 1 (6) 5 (12) ns
Sum 11–21, no of patients (%) 1 (6) 4 (9) ns
HAD, sum D, median ns
Sum 0–7, no of patients (%) 16 (94) 40 (93) ns
Sum 8–10, no of patients (%) 1 (6) 2 (5) ns
Sum 11–21, no of patients (%) 0 1(2) ns
Reported subjective complaints
Headache (%) 6/20 (30) 23/46 (50) ns
Neck stiffness (%) 0 4/44 (9) ns
Photophobia (%) 7/18 (39) 8/46 (17) ns
Phonophobia (%) 7/18 (39) 12/46 (26) ns
Neurological symptomsc (%) 13/20 (65) 11/46 (24) 0.001
Concentration difficulties (%) 12/20 (60) 13/46 (28) 0.015
Memory problems (%) 14 /20 (70) 17/46 (37) 0.013
Emotional changed (%) 7/18 (39) 13/46 (28) ns
Extensive tiredness (%) 15/20 (75) 18/46 (39) 0.007
Sleep disturbancee (%) 14/20 (70) 14/46 (30) 0.003
Table 3. Short- term outcomes (at 2 months). Data are presented as number of patients (%), amean (SD) or 
bmedian (IQR). cMost reported were difficulty finding words, reduced coordination, urinary retention. dFeeling 
of anxiousness or mood disorder, eincreased need of sleep. GOSE: Glasgow Outcome Scale Extended, SF-36: 
Survey Short Form, HAD: Hospital Anxiety and Depression Scale.
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Results
patient characteristics prior to discharge. Three patients (11%) with encephalitis died during the hos-
pital stay. Etiology was identified in only 5/20 surviving patients with encephalitis. For patients with ASM, the 
causing agent was identified in 34/ 46 (74%). Enterovirus was the most common cause, identified in 43% of 
patients with ASM. Interestingly, we identified Borrelia burgdorferi as causing agent in two patients with enceph-
alitis, as well as in one patient with aseptic meningitis. Clinical characteristics, findings and treatment of patients 
at admission are shown in Table 2.
Short-term outcome. At a median of 67 days (range 36–168), all employed patients with encephalitis 
and 37% of the ASM patients had reduced workability. Moderate disability, i.e. GOSE ≤ 6, was found in 39% of 
patients with ASM, and in 75% of patients with encephalitis (Table 3). Of patients with ASM, 63% reported daily 
symptoms, while all but one patient (95%) with encephalitis experienced symptoms (Table 3). In general, scores of 
the SF-36 subscales and the component summary score (PCS and MCS) were lower for patients with encephalitis 
compared to ASM patients (Table 3). For encephalitis, both PCS and MCS were significantly lower compared to 
the expected population mean of 50 (PCS 43.6, p = 0.005 and MCS 44.9, p = 0.014) (Fig. 2). For ASM, only PCS 
was significantly lower compared to population mean (PCS 46.7, p = 0.042).
Long-term outcome and neurocognitive function. The education level was not different between 
the groups, but the education level was high, 15.5 ± 3 yrs. Moreover, tested encephalitis patients were older 
(53.5 ± 16.5 vs 37.2 ± 9.7, p = 0.007) and more often men (8/11 (72%) vs 3/13 (23%), p = 0.014). The neuropsy-
chological tests were poorer in the encephalitis group regarding fine motor and psychomotor skills, as well as 
learning and memory (Table 4). The total number of patients with z-scores below −1 SD was 14% in the enceph-
alitis group compared to 3% in the ASM group.
Association of short-term outcome with KP metabolites and markers of inflammation in CSF 
at admittance. We have previously reported markedly enhanced neopterin and IDO levels and a lower ratio 
of KYNA/(3-HK + QA), particularly in patients with encephalitis, compared to healthy controls21. These param-
eters in the current sub-population are shown in Fig. 3. To evaluate whether outcome could be related to level of 
immune activation or activation of the KP, the summary scores of the SF-36 (i.e. PCS and MCS) were used. In 
patients with encephalitis there was a strong positive correlation between MCS and the putative neuroprotective/
neurotoxic ratio of KYNA/ (3-HK + QA) (Rho 0.9, p = 0.014) and strong inverse correlation with neopterin, as 
a marker of Th1 cell activation (Rho −0.9, p = 0.007), and IDO (Rho −0.9, p = 0.014) (Table 5). No correlation 
was found between number of days admitted, CSF white cell counts (WBC) or CSF protein at hospital admittance 
and PCS and MCS.
Discussion
We evaluated short- and long-term outcome, workability, HRQoL and neuropsychological functioning in patients 
with encephalitis and ASM of various and unknown etiology. Our main findings were 1) encephalitis and ASM 
patients have low short-term HRQoL scores compared to the normal population and displayed reduced workabil-
ity, with more pronounced reductions in encephalitis, 2) in encephalitis, HRQoL as reflected by MCS, correlated 
with a putative neurotoxic imbalance of the KP, and 3) encephalitis displayed more long-term neurocognitive 
deficits.
Persisting complaints after surviving encephalitis are well known, especially for HSV1-encephalitis3,4. Less 
is known on outcome and neurocognitive functioning in patients with encephalitis with non-HSV or unknown 
etiology and ASM. Although comparison with other studies is hampered by different test batteries and time 
to follow-up, our data support previous findings of reduced HRQoL for patients with ASM, at least on the 
short-term8. However, after 12 months the number of neurocognitive tests with a z-score below −1 SD in the 
Figure 2. Mean scores of SF-36 subscales, PCS and MCS of patients with aseptic meningitis and encephalitis 
compared to the estimated population mean at follow-up at two months. Asterisks denotes significant difference 
vs estimated population mean; *p < 0.05, **p ≤ 0.001. For encephalitis both PCS (p = 0.005) and MCS 
(p = 0.014) were below the population mean, while for ASM, only PCS was below (p = 0.042). PF: Physical 
functioning, RP: Role physical, RE: Role emotional, BP: Bodily pain, GH: General health, VT: Vitality, SF: 
Social functioning, MH: Mental health, PCS: Physical Component Summary score, MCS: Mental Component 
Summary score.
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ASM group were low (3%), indicating good recovery with no/minimal neurocognitive sequelae. For patients 
with encephalitis, although no deficits were found in some individuals, the higher numbers (14%) of neuropsy-
chological tests with a z-score below −1 SD indicate more neurocognitive deficits in this group. A major finding 
in this study was that for patients with encephalitis, MCS (as a marker of HRQoL) was inversely correlated with 
neopterin levels. IFN-γ is an activator of IDO, the first step of the KP, and neopterin is thought to be a stable and 
reliable marker of IFN-γ activity43,44. The CSF level of IFN-γ at time of diagnosis has been associated with worse 
outcome at 3 months in patients with HSV1-encephalitis13. During inflammation, activation of the KP results 
in the formation of metabolites with potential neurotoxic (e.g. QA and 3-HK) and neuroprotective (e.g. KYNA) 
effects45. For the putatively neuroprotective/neurotoxic ratio of the KP (i.e. KYNA/(3-HK + QA)), a positive asso-
ciation was found. Others have found that worse outcome is associated with low KYNA levels during the acute 
phase, while elevated levels of KYNA has been detected more than one year after onset of HSV1 encephalitis15. 
KYNA is an antagonist of the NMDA receptor, and may antagonize the neurotoxic effect exerted by the QA. 
However, activation of the KP and elevated levels of KYNA have also been associated with cognitive impair-
ment and psychotic symptoms, possibly through antagonism of the alpha- 7 nicotinic acetylcholine receptor 







Ruff 2&7 Total Accuracya 94.9 ± 13.5 102.9 ± 8.6 ns
Digit span Totala 24.0 ± 8.8 28.7 ± 6.1 ns
Psychomotor speed
Ruff 2&7 Total Speeda 84.6 ± 33.1 94.9 ± 19.2 ns
Trail Making test 1b 24.6 ± 8.3 17.8 ± 6.4 ns
Trail making test 2b 41.6 ± 28.2 27.4 ± 7.3 0.008
Trail making test 3b 43.4 ± 37.0 28.3 ± 9.0 0.019
Color word interference test 1b 34.7 ± 8.4 27.3 ± 3.5 0.010
Color word interference test 2b 24.6 ± 4.6 20.8 ± 4.6 ns
Digit symbola 57.5 ± 16.8 72.6 ± 13.2 ns
Fine motor speed
Pegboard Dominant Handb 76.5 ± 18.3 60.0 ± 5.2 <0.001
Pegboard Non-dominant Handb 83.6 ± 25.1 67.1 ± 8.5 0.028
Verbal learning and 
memory
CVLT Total learninga 53.6 ± 11.3 64.9 ± 7.4 0.040
CVLT short term memorya 11.0 ± 4.0 14.4 ± 2.1 0.005
CVLT long term memorya 11.9 ± 3.1 15.0 ± 1.5 0.008
CVLT recognitiona 15.2 ± 1.1 15.7 ± 0.6 0.038
CVLT false positivea 1.6 ± 3.9 0.8 ± 0.3 0.022
Visual learning and 
memory
BVMT Total learninga 23.9 ± 8.1 27.9 ± 4.7 0.049
BVMT long term memory a 9.6 ± 2.2 10.5 ± 1.3 ns
Vocabulary (total correct) Vocabularya 31.3 ± 12.0 40.0 ± 7.9 ns
Visuospatial function Block designa 41.7 ± 13.7 45.9 ± 9.8 ns
Executive function
Trail making test 4b 52.1 ± 16.5 77.1 ± 31.1 ns
Color word interference test 3b 70.6 ± 18.1 49.5 ± 2.9 0.011
Color word interference test 4b 71.5 ± 15.7 58.4 ± 11.0 ns
Word Fluency test FASa 42.4 ± 14.5 51.0 ± 14.5 ns
Symptom burden
SCL-90a
SCL-90 somatization 8.5 ± 12.1 5.2 ± 6.8 ns
SCL-90 obsessive compulsive 5.7 ± 4.9 5.0 ± 5.7 ns
SCL-90 interpersonal sensitivity 1.8 ± 2.2 1.9 ± 2.1 ns
SCL-90 depression 3.6 ± 4.7 5.4 ± 7.4 ns
SCL-90 anxiety 1.9 ± 3.0 3.1 ± 3.8 ns
SCL-90 hostility 0.6 ± 0.8 1.7 ± 2.2 0.021
SCL-90 phobia 0.5 ± 0.9 0.5 ± 1.0 ns
SCL-90 paranoid anxiety 0.4 ± 0.5 0.8 ± 1.1 ns
SCL-90 psychoticism 0.4 ± 0.7 1.1 ± 1.4 ns
SCL-90 GSI 26.5 ± 28.0 28.0 ± 8.3 ns
BRIEFa
BRIEF-A Behavioural









Table 4. Neuropsychological test results, SCL-90 and BRIEF (12 months, raw scores). Raw scores of test given 
as apoints, and bseconds CVLT: Californian Verbal Learning Test, BVMT: Brief Visuospatial Memory Test, 
BRIEF: Behavior Rating Inventory of Executive Function, SCL: Symptom Checklist 90.
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the acute-phase may be associated with worsened HRQoL for patients with encephalitis. This influence may, 
at least partly be mediated by increased IFN−γ activity reflecting increased Th1 cellular immune activity with 
neopterin as a reliable marker.
The strength of this study is the prospective character and the reported findings of reduced HRQoL and 
persisting complains for as long as two months after discharge. Especially for patients with ASM these findings 
are of clinical relevance. Moreover, the proportion of identified cause in patients with ASM is high (74%), and 
shows, as suggested by others, that extensive utilization of PCR in all patients with ASM may increase the number 
of patients with identified cause47. The study has some limitations. The relatively high proportion of patients lost 
to follow-up (26% and 28% in the encephalitis and the ASM group, respectively) may have biased the results. In 
the encephalitis group, three patients died as a consequence of their encephalitis, and for three patients comor-
bidity such as cancer and psychiatric disease led to exclusion from the follow-up study. Moreover, patients that 
were lost to follow up in the ASM group (Fig. 1) may have represented the healthiest of those diagnosed with 
ASM. However, except from a higher proportion of detected agents in the encephalitis group not included in 
the follow-up study, there were no significant differences in clinical and epidemiological characteristics between 
included and not included patients. Furthermore, pathogenesis and outcome of CNS infections has been shown 
to depend on the causing agent48. However, because of heterogeneous etiology and the small study groups, no 
sub-analyses could be done, and the statistical power of the analyses is low. We suggest that the reduced HRQoL 
and neurocognitive functioning in the encephalitis group is caused by the parenchymal character of the infec-
tion, including KP activation, but older age and male dominance in the encephalitis group might cause a bias. 
Likewise, the influence of CNS infection on HRQoL may be overestimated, especially for the ASM group, which 
consisted of many females in their thirties with a busy family life. Lastly, correlation does not mean causality and 
given the limited sample size and the explorative nature of the study, there is a need for larger studies to evaluate 
these issues.
In conclusion, encephalitis, but also ASM have substantial short-term influence on HRQoL and workability. 
However, according to this study, the long-term prognosis for ASM patients seems good. Our study suggests a link 
between impaired HRQoL and metabolites of the KP in patients with encephalitis that might represent a novel tar-
get for therapy. This should be further evaluated in larger encephalitis cohorts with CSF analyses during follow-up.
Figure 3. Neopterin, KYN/TRP ratio and KYNA/(3-HK + QA) for patients with encephalitis (n = 7) and 
ASM (n = 10) measured at admission in comparison with a previously reported control group consisting 
of patients with no pleocytosis in the CSF21. Data shown are medians with IQR. Asterisks above patients 
groups indicate significant difference vs controls (Mann Whitney U test); **p < 0.01, ***p < 0.001. aKYN/
TRP ratio as a measure of IDO activity. KYN: kynurenine, TRP: tryptophan, KYNA: kynurenic acid, 3-HK: 
3-hydroxykynurenine, QA: quinolinic acid.
Encephalitis (n = 7) Aseptic meningitis (n = 10)
PCS MCS PCS MCS
KYNA/(3-HK + QA) −0.4 (p = 0.9) 0.9 (p = 0.014) 0.1 (p = 0.7) −0.5 (p = 0.1)
Neopterin 0.07 (p = 0.9) −0.9 (p = 0.007) −0.2 (p = 0.7) 0.09 (p = 0.8)
IDO 0.143 (p = 0.8) −0.9 (p = 0.014) −0.2 (p = 0.8) 0.006 (p = 0.9)
Table 5. Correlations of PCS and MCS at two months with KP metabolites and neopterin in CSF Data shown 
are obtained by Spearman’s rank correlation (p-value). KP: Kynurenine pathway, KYNA: Kynurenic acid, 
3-HK: 3-hydroxykynurenine, QA: Quinolinic acid, IDO: KYN (nmol)/TRP(μmol), PCS: Physical Component 
Summary score, MCS: Mental Component Summary score.
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